KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) EPS (Weighted Average and Diluted) (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $26.71 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 204.46% to $26.71 in Q4 2025 year-over-year; TTM through Dec 2025 was $27.85, a 142.82% increase, with the full-year FY2025 number at $27.85, up 142.61% from a year prior.
  • EPS (Weighted Average and Diluted) was $26.71 for Q4 2025 at Bio-Rad Laboratories, up from -$12.7 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $130.02 in Q3 2021 to a low of -$112.5 in Q1 2022.
  • A 5-year average of -$1.98 and a median of $2.98 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 446.58% in 2022, then skyrocketed 541.21% in 2024.
  • Bio-Rad Laboratories' EPS (Weighted Average and Diluted) stood at -$52.54 in 2021, then surged by 152.87% to $27.78 in 2022, then crashed by 56.3% to $12.14 in 2023, then crashed by 310.63% to -$25.57 in 2024, then soared by 204.46% to $26.71 in 2025.
  • Per Business Quant, the three most recent readings for BIO's EPS (Weighted Average and Diluted) are $26.71 (Q4 2025), -$12.7 (Q3 2025), and $11.55 (Q2 2025).